FLNA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026
Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
11.3M
+20.0%
9.4M
-15.9%
11.2M
R&D
3.9M
+17.1%
3.3M
-27.3%
4.5M
SG&A
7.4M
+21.6%
6.1M
-8.1%
6.6M
Operating Income
-11274000
-20.0%
-9393000
+15.9%
-11168000
EBITDA
-11064000
-20.9%
-9149000
+16.3%
-10925000
Net Income
-10726000
-24.7%
-8603000
+16.7%
-10331000
EPS (Basic)
$-0.22
-22.2%
$-0.18
+14.3%
$-0.21
EPS (Diluted)
$-0.22
-22.2%
$-0.18
+14.3%
$-0.21
Shares (Diluted)
48.5M
+0.3%
48.3M
-1.8%
49.2M
Filana Therapeutics (FLNA) — Financials